Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trialAleix Prat, Joaquín Gavilá, Neus Ferrer et al.|The Lancet Oncology|2019Cited by 199
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluationAleix Prat, PierFranco Conte, Valentina Guarneri et al.|The Lancet Oncology|2020Cited by 75
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trialValentina Guarneri, Aleix Prat, Fara Brasó‐Maristany et al.|EBioMedicine|2022Cited by 42
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancerMercedes Marín‐Aguilera, Laia Paré, Pedro Jares et al.|ESMO Open|2024Cited by 27
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1Fara Brasó‐Maristany, Valentina Guarneri, Gaia Griguolo et al.|JNCI Journal of the National Cancer Institute|2022Cited by 25